遗传风险评分改善抗凝相关脑出血的风险分层
研究从1545例脑出血(ICH)病例和1481例对照的全基因组关联数据构建153个遗传风险评分,并在UK Biobank的431例ICH病例和431例匹配对照中验证,选出解释ICH风险方差最大的评分,在5530例抗凝使用者中测试其对 incident ICH 的预测。在平均随访11.9年期间发生94例ICH,最高遗传风险评分三分位与最低三分位相比 incident ICH 风险增加两倍(HR 2.08,95%CI 1.22-3.56);将高遗传风险加分加入基于HAS-BLED的临床风险评分后,每增加1分的HR从1.24(95%CI 1.01-1.53)变为1.33(95%CI 1.11-1.59),C指数从0.53升至0.57,校准维持(两者集成校准指数均为0.001),高风险分类改善19%,净重分类改善0.10。
要点
- 在抗凝使用者中,最高遗传风险评分三分位与最低三分位相比,incident ICH 风险增加两倍(HR 2.08,95%CI 1.22-3.56)。
- 基于HAS-BLED的临床风险评分每增加1分预测 incident ICH 的HR为1.24(95%CI 1.01-1.53)。
- 加入高遗传风险加分后每增加1分HR为1.33(95%CI 1.11-1.59),C指数0.57 vs 0.53,校准维持(集成校准指数均为0.001)。
核心结论
- 在抗凝使用者中,纳入基因组信息的预测评分在ICH风险分层方面优于单独临床风险评分,并可用于临床决策。
研究设计与样本
- 从1545例ICH病例和1481例对照的全基因组关联数据构建153个遗传风险评分,并在UK Biobank的431例ICH病例和431例匹配对照中验证。
- 选出解释ICH风险方差最大的评分,在5530例抗凝使用者的独立队列中测试其对 incident ICH 的预测。
- 将基于HAS-BLED评分8/9个成分的临床风险评分与额外加1分高遗传ICH风险的联合临床和遗传风险评分进行比较。
主要发现
- 在抗凝个体中,平均随访11.9年期间发生94例ICH。
- 与最低遗传风险评分三分位相比,最高三分位与 incident ICH 风险增加两倍相关(HR 2.08,95%CI 1.22-3.56)。
- 临床风险评分预测 incident ICH 的HR为每增加1分1.24(95%CI 1.01-1.53)。
- 加入高遗传ICH风险1分后关联更强(HR 每增加1分1.33,95%CI 1.11-1.59),风险分层改善(C指数0.57 vs 0.53),校准维持(两者集成校准指数均为0.001)。
- 新的临床和遗传风险评分在ICH个体中高风险分类改善19%,净重分类改善0.10。
关键数值与推荐
- 最高遗传风险评分三分位 vs 最低三分位:HR 2.08(95%CI 1.22-3.56)。
- 临床风险评分每增加1分:HR 1.24(95%CI 1.01-1.53)。
- 联合临床和遗传风险评分每增加1分:HR 1.33(95%CI 1.11-1.59)。
- C指数:联合评分0.57 vs 临床评分0.53。
- 集成校准指数:联合评分0.001,临床评分0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracerebral hemorrhage (ICH) is the most devastating adverse outcome for patients on anticoagulants. Clinical risk scores that quantify bleeding risk can guide decision-making in situations when indication or duration for anticoagulation is uncertain. We investigated whether integration of a genetic risk score into an existing risk factor-based CRS could improve risk stratification for anticoagulation-related ICH. METHODS: We constructed 153 genetic risk scores from genome-wide association data of 1545 ICH cases and 1481 controls and validated them in 431 ICH cases and 431 matched controls from the population-based UK Biobank. The score that explained the largest variance in ICH risk was selected and tested for prediction of incident ICH in an independent cohort of 5530 anticoagulant users. A CRS for major anticoagulation-related hemorrhage, based on 8/9 components of the HAS-BLED score, was compared with a combined clinical and genetic risk score incorporating an additional point for high genetic risk for ICH. RESULTS: Among anticoagulated individuals, 94 ICH occurred over a mean follow-up of 11.9 years. Compared with the lowest genetic risk score tertile, being in the highest tertile was associated with a two-fold increased risk for incident ICH (hazard ratio, 2.08 [95% CI, 1.22-3.56]). Although the CRS predicted incident ICH with a hazard ratio of 1.24 per 1-point increase (95% CI [1.01-1.53]), adding a point for high genetic ICH risk led to a stronger association (hazard ratio of 1.33 per 1-point increase [95% CI, 1.11-1.59]) with improved risk stratification (C index 0.57 versus 0.53) and maintained calibration (integrated calibration index 0.001 for both). The new clinical and genetic risk score showed 19% improvement in high-risk classification among individuals with ICH and a net reclassification improvement of 0.10. CONCLUSIONS: Among anticoagulant users, a prediction score incorporating genomic information is superior to a clinical risk score alone for ICH risk stratification and could serve in clinical decision-making.
引用
- Mayerhofer E, Parodi L, Prapiadou S, et al. Genetic Risk Score Improves Risk Stratification for Anticoagulation-Related Intracerebral Hemorrhage. Stroke. 2023. PMID: 36756894. doi:10.1161/STROKEAHA.122.041764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。